AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteMoxonidine is a new-generation centrally-acting antihypertensive drug. It may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction.
More Information Supplier PageMoxonidine is a selective agonist at the imidazoline receptor subtype 1 (I1). Moxonidine causes a decrease in sympathetic nervous system activity and, therefore, a decrease in blood pressure.
More Information Supplier PageMoxonidine is a selective agonist at the imidazoline receptor subtype 1 (I1). Moxonidine causes a decrease in sympathetic nervous system activity and, therefore, a decrease in blood pressure.
More Information Supplier PageMoxonidine is a selective agonist at the imidazoline receptor subtype 1 (I1). Moxonidine causes a decrease in sympathetic nervous system activity and, therefore, a decrease in blood pressure.
More Information Supplier PageMoxonidine is a selective agonist at the imidazoline receptor subtype 1 (I1). Moxonidine causes a decrease in sympathetic nervous system activity and, therefore, a decrease in blood pressure.
More Information Supplier PageMoxonidine hydrochloride is a centrally acting antihypertensive agent.
More Information Supplier PageMoxonidine hydrochloride is a centrally acting antihypertensive agent.
More Information Supplier PageMoxonidine hydrochloride is a centrally acting antihypertensive agent.
More Information Supplier PageMPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.
More Information Supplier PageMPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.
More Information Supplier PageMPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.
More Information Supplier PageMPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.
More Information Supplier PageMPEP is a potent, highly selective non-competitive antagonist at the mGlu5a receptor subtype (IC50 = 36 nM) while having no agonist or antagonist activities at the mGlu1b receptor at concentrations up to 30 uM.
More Information Supplier PageMPEP is a potent, highly selective non-competitive antagonist at the mGlu5a receptor subtype (IC50 = 36 nM) while having no agonist or antagonist activities at the mGlu1b receptor at concentrations up to 30 uM.
More Information Supplier PageMPEP is a potent, highly selective non-competitive antagonist at the mGlu5a receptor subtype (IC50 = 36 nM) while having no agonist or antagonist activities at the mGlu1b receptor at concentrations up to 30 uM.
More Information Supplier PageMPEP hydrochloride is a potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors.
More Information Supplier PageMPEP hydrochloride is a potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors.
More Information Supplier PageMPEP hydrochloride is a potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors.
More Information Supplier PageMPEP hydrochloride is a potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors.
More Information Supplier PageMPEP hydrochloride is a potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors.
More Information Supplier PageMPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1
More Information Supplier PageMPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1
More Information Supplier PageMPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1
More Information Supplier PageMPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1
More Information Supplier PageMPTP hydrochloride induced reduction in the DOPAC HVA/dopamine (DA) ratio and increase in striatal ascorbate (AS) oxidation in rats.
More Information Supplier PageMPTP hydrochloride induced reduction in the DOPAC HVA/dopamine (DA) ratio and increase in striatal ascorbate (AS) oxidation in rats.
More Information Supplier PageMPTP hydrochloride induced reduction in the DOPAC HVA/dopamine (DA) ratio and increase in striatal ascorbate (AS) oxidation in rats.
More Information Supplier PageMRK 560 is an orally bioavailable gamma-secretase inhibitor with the ability to markedly reduce Abeta peptide in the brain and CSF of the rat and confirm the utility of the rat for assessing the effects of gamma-secretase inhibitors on central nervous system Abeta(40) levels in vivo.
More Information Supplier PageMRK 560 is an orally bioavailable gamma-secretase inhibitor with the ability to markedly reduce Abeta peptide in the brain and CSF of the rat and confirm the utility of the rat for assessing the effects of gamma-secretase inhibitors on central nervous system Abeta(40) levels in vivo.
More Information Supplier PageMS-275 (Entinostat) is a potent HDAC inhibitor with IC50 of 0.3 and 8uM for HDAC1 and HDAC3, respectively.
More Information Supplier PageMS-275 (Entinostat) is a potent HDAC inhibitor with IC50 of 0.3 and 8uM for HDAC1 and HDAC3, respectively.
More Information Supplier PageMS-275 (Entinostat) is a potent HDAC inhibitor with IC50 of 0.3 and 8uM for HDAC1 and HDAC3, respectively.
More Information Supplier PageMS-275 (Entinostat) is a potent HDAC inhibitor with IC50 of 0.3 and 8uM for HDAC1 and HDAC3, respectively.
More Information Supplier PageMS-275 (Entinostat) is a potent HDAC inhibitor with IC50 of 0.3 and 8uM for HDAC1 and HDAC3, respectively.
More Information Supplier PageMS436 is a diazobenzene-based small-molecule inhibitor for the BRD4 bromodomains with a Ki value of 30-50 nM.
More Information Supplier PageMS436 is a diazobenzene-based small-molecule inhibitor for the BRD4 bromodomains with a Ki value of 30-50 nM.
More Information Supplier PageMS436 is a diazobenzene-based small-molecule inhibitor for the BRD4 bromodomains with a Ki value of 30-50 nM.
More Information Supplier PageMSDC-0160 is a prototype mTOT-modulating insulin sensitizer being studied to treat diabetes and Alzheimer’s disease.
More Information Supplier Page
